Valuation: Abpro Corporation

Market Cap 2.36M 2.06M 1.94M 1.76M 3.3M 226M 3.32M 23.26M 8.98M 115M 8.86M 8.66M 370M P/E 2024
-2.41x
P/E 2025 -3.27x
Enterprise Value 2.44M 2.13M 2.01M 1.82M 3.42M 234M 3.43M 24.05M 9.28M 119M 9.16M 8.96M 383M EV / Sales 2024
497x
EV / Sales 2025 -
Free-Float
83.91%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.36M
+0.11%+1.98%-0.04%+9.69% 46.18B
-1.12%+1.78%+40.07%+27.26% 44.35B
-3.04%-6.29%+322.27%+517.36% 42.21B
-0.74%+1.25%+2.32%+67.94% 40.19B
-0.50%-0.77%+11.86%+40.41% 29.83B
-0.46%+4.22%+21.99%+124.21% 17.17B
-0.97%-10.17% - - 15.7B
-0.57%+7.78%+21.76%+38.08% 15.32B
-3.28%-3.07%-8.54%-37.61% 13.09B
Average -1.06%+1.67%+51.46%+98.42% 29.34B
Weighted average by Cap. -1.12%+1.63%+66.14%+119.41%

Financials

2024 2025
Net sales 183K 160K 151K 137K 256K 17.56M 257K 1.8M 696K 8.93M 687K 672K 28.73M -
Net income -7.23M -6.31M -5.95M -5.41M -10.13M -694M -10.17M -71.33M -27.52M -353M -27.17M -26.56M -1.14B -2.89M -2.52M -2.38M -2.16M -4.05M -278M -4.07M -28.52M -11.01M -141M -10.86M -10.62M -454M
Net Debt 478K 417K 394K 357K 670K 45.87M 672K 4.71M 1.82M 23.32M 1.8M 1.76M 75.03M 80K 69.76K 65.87K 59.81K 112K 7.68M 113K 789K 304K 3.9M 301K 294K 12.56M
Logo Abpro Corporation
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!